Skip to content
Peptide research

TB-500

Also known as Thymosin Beta-4 Fragment
Category
Tissue Repair & Recovery
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A synthetic fragment of thymosin beta-4, marketed for tendon, muscle, and ligament recovery. The fragment's evidence is limited to preclinical work; human safety and efficacy have not been established. The cited dry-eye trial concerns full-length thymosin beta-4. Because thymosin beta-4 drives new blood-vessel growth, a theoretical tumor concern is unresolved. Not FDA-approved, restricted by the FDA over safety, and mostly sold as unregulated products online.

Read Full record

Studied uses & evidence

Studied uses(7)

  • Wound healing

    Medium

    The 42–61% result came from rat wounds treated with full-length thymosin beta-4. Its human ulcer trials do not establish TB-500 fragment efficacy.

  • Cardiac repair

    Low

    Full-length thymosin beta-4 has preclinical cardiac findings. The cited RGN-352 record does not establish human scar reduction, and no TB-500 fragment cardiac trial was identified.

  • Corneal healing

    Medium

    A small full-length thymosin beta-4 eye-drop trial showed a nonsignificant four-week healing trend; it did not test TB-500.

Evidence limits

Evidence Level
Preclinical

TB-500 fragment has no established human safety or efficacy evidence. The cited Phase I–III programs concern full-length thymosin beta-4, including RGN-259 eye drops, and cannot establish benefits or safety for injected TB-500.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Active cancer

    High

    TB-500 promotes cell migration and angiogenesis, which may accelerate tumor growth or metastasis.

  • Recent head injury with active bleeding

    Moderate

    Angiogenic properties may complicate recovery from hemorrhagic injuries.

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data.

Risk summary(6)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Not FDA-approved for any indication

    High
  • FDA's drug reviewers found safety concerns and recommended against listing it; compounding is limited to the conditions of a draft interim HHS policy

    High
  • Promotes angiogenesis; theoretical concern for tumor vascularization

    Theoretical
  • Limited long-term human safety data

    Moderate
  • Full-length thymosin beta-4's ARISE-3 dry-eye trial missed its co-primary endpoints; this was not a TB-500 fragment trial

    Moderate
  • Unregulated products sold online

    High
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.